Company Profile
Foghorn Therapeutics Stock Price, News & Analysis
- Ticker:
- FHTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.57 USD (+14.14%)
Close
Last updated: August 6, 2026
213M USD
Market cap
Why the stock is moving
Following the latest company update, “Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update”, FHTX closed up 14.1% at $5.57 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Business overview
Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Foghorn sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on translational data, target validation, and the possibility of building a new oncology platform.
Position Within the Biotechnology Landscape
Foghorn is a high-catalyst oncology name with strong dependence on early data quality.
Future catalysts
Foghorn’s next three months are about its chromatin-regulation oncology programs and any data that show the platform can still produce differentiated human results. The market will care most about whether the synthetic-lethality thesis can keep moving forward.
Recent news
- 01
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Source: Foghorn Therapeutics
- 02
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Source: Foghorn Therapeutics
- 03
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Source: Foghorn Therapeutics
- 04
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Source: Foghorn Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics (FHTX) most recently closed at 5.57 USD, a +14.14% move versus the previous session.
What is the market cap of Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics currently has a market capitalization of 213M USD on BioPharmSignal.
What does Foghorn Therapeutics do?
Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.
On which exchange is FHTX stock listed?
Foghorn Therapeutics (FHTX) is associated with NASDAQ, United States, Biopharma.
What is Foghorn?
Foghorn’s next three months are about its chromatin-regulation oncology programs and any data that show the platform can still produce differentiated human results.
Which conditions is Foghorn Therapeutics targeting with Foghorn?
Foghorn Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Foghorn Therapeutics describe recent progress with Foghorn?
Foghorn’s next three months are about its chromatin-regulation oncology programs and any data that show the platform can still produce differentiated human results.
What is Therapeutics?
Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets.